Price
CHART BY
Frequently asked questions
What is Valneva's market capitalization?
What is the Earnings Per Share (EPS) for Valneva?
What are the analyst ratings and target price for Valneva's stock?
What is Valneva's revenue over the trailing twelve months?
What is the free cash flow of Valneva?
How many employees does Valneva have, and what sector and industry does it belong to?
What is the free float of Valneva's shares?
Financials
- Market Cap
- $525.53M
- EPS (TTM)
- -$0.579
- Free Float
- 139.89M
- Revenue (TTM)
- $206.71M
- Free Cashflow (TTM)
- -$82.35M
Pricing
- 1D span
- $3.034$3.264
- 52W span
- $1.814$4.676
Analyst Ratings
The price target is $8.069 and the stock is covered by 8 analysts.
Buy
7
Hold
1
Sell
0
Information
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three proprietary travel vaccines: IXIARO, DUKORAL, and IXCHIQ. The IXIARO is an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis in adults, adolescents, children, and infants aged two months and older. The DUKORAL is a drinkable vaccine that helps prevent diarrhea caused by heat-labile toxin-producing ETEC, as well as cholera. The IXCHIQ is a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also offers additional vaccines, including VLA1553, VLA15, VLA160, VLA200, VLA1601 and others. Valneva was founded on May 28, 2013 and is headquartered in Saint-Herblain, France.
- Employees
- 713
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- FR0004056851
- Primary Ticker
- VLA